论文部分内容阅读
目的观察顺铂、环磷酰胺交替腹腔热灌注化疗治疗癌性积液的临床疗效。方法将癌性腹腔积液患者21例随机分为两组,顺铂、环磷酰胺交替腹腔热灌注化疗组以及环磷酰胺腹腔灌注化疗组。每周做治疗2次,共做4～6周。然后评估疗效及不良反应。结果顺铂、环磷酰胺交替腹腔热灌注化疗组有效率86.67%(13/21),明显高于环磷酰胺化疗组50%(3/6,P=0.019),而腹腔热灌注化疗组的不良反应发生率与对照组无明显差别(P>0.05)。结论顺铂、环磷酰胺交替腹腔热灌注化疗治疗癌性积液安全、操作简单、不良反应耐受性好,是控制恶性腹腔积液的有效方法。
Objective To observe the clinical efficacy of cisplatin and cyclophosphamide alternating intraperitoneal hyperthermic perfusion chemotherapy for cancerous effusion. Methods Twenty-one patients with cancerous ascites were randomly divided into two groups: cisplatin, cyclophosphamide alternating intraperitoneal hyperthermic perfusion chemotherapy group and cyclophosphamide intraperitoneal perfusion chemotherapy group. Treatment twice a week, a total of 4 to 6 weeks. Then assess the efficacy and adverse reactions. Results The response rates of cisplatin and cyclophosphamide in intraperitoneal hyperthermic perfusion chemotherapy group were 86.67% (13/21), which were significantly higher than those in cyclophosphamide chemotherapy group (50%, 3/6, P = 0.019) The incidence of adverse reactions and the control group no significant difference (P> 0.05). Conclusions Cisplatin and cyclophosphamide alternating intraperitoneal hyperthermic perfusion chemotherapy is safe and effective in treating malignant effusion. The operation is simple and the adverse reaction is well tolerated. It is an effective method to control malignant ascites.